Bio Techne Stock Current Valuation
| T1CH34 Stock | 13.08 0.36 2.68% |
Valuation analysis of Bio Techne helps investors to measure Bio Techne's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Bio Techne's price fluctuation is not too volatile at this time. Calculation of the real value of Bio Techne is based on 3 months time horizon. Increasing Bio Techne's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Bio Techne is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Bio Stock. However, Bio Techne's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.08 | Real 11.45 | Hype 13.08 | Naive 11.62 |
The real value of Bio Stock, also known as its intrinsic value, is the underlying worth of Bio Techne Company, which is reflected in its stock price. It is based on Bio Techne's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Bio Techne's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Bio Techne helps investors to forecast how Bio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bio Techne more accurately as focusing exclusively on Bio Techne's fundamentals will not take into account other important factors: Bio Techne Company Current Valuation Analysis
Bio Techne's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Bio Techne Current Valuation | 73.29 B |
Most of Bio Techne's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Bio Techne has a Current Valuation of 73.29 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Brazil stocks is significantly lower than that of the firm.
Bio Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.Bio Techne is currently under evaluation in current valuation category among its peers.
Bio Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0771 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 73.29 B | |||
| Shares Outstanding | 4.72 B | |||
| Price To Book | 7.19 X | |||
| Price To Sales | 65.05 X | |||
| Revenue | 1.11 B | |||
| Gross Profit | 758.09 M | |||
| EBITDA | 413.76 M | |||
| Net Income | 272.05 M | |||
| Total Debt | 243.41 M | |||
| Book Value Per Share | 0.38 X | |||
| Cash Flow From Operations | 325.27 M | |||
| Earnings Per Share | 0.28 X | |||
| Number Of Employees | 3 K | |||
| Beta | 1.21 | |||
| Market Capitalization | 60.28 B | |||
| Total Asset | 2.29 B | |||
| Annual Yield | 0 % | |||
| Net Asset | 2.29 B | |||
| Last Dividend Paid | 0.32 |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bio Stock
Bio Techne financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Techne security.